MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc. - Common Stock (NQ:DNLI)

24.00 -0.67 (-2.72%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 807,541
Open 24.42
Bid (Size) 24.00 (2,200)
Ask (Size) 24.01 (400)
Prev. Close 24.67
Today's Range 23.92 - 24.61
52wk Range 12.58 - 27.30
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript ↗
AVLAYAH revenue hit $3.6M in first full quarter post-approval. 
Via The Motley Fool
Topics Earnings
Denali Therapeutics (NASDAQ:DNLI) Shows Perfect Technical Setup for a Breakout ↗
Via Chartmill

Performance

YTD
+47.5%
+47.5%
1 Month
-0.2%
-0.2%
3 Month
+14.6%
+14.6%
6 Month
+12.0%
+12.0%
1 Year
+53.8%
+53.8%

More News

Read More
News headline image
Denali Therapeutics Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
Denali Therapeutics (NASDAQ:DNLI) Drops as Q2 AVLAYAH Revenue Misses Estimates ↗
Via Chartmill
News headline image
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval ↗
Via MarketBeat
News headline image
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval ↗
Via The Motley Fool
Topics Regulatory Compliance
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial Highlighting Biotech’s Shift Toward Science-Driven Asset Valuation
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
When Science Becomes an Asset: How Advancing Drug Pipelines Are Driving Real-Time Valuation in Biotech
From BioMedWire
Via GlobeNewswire
News headline image
Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via GlobeNewswire
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
News headline image
Biogen (BIIB) Q4 Earnings Preview: The "New Biogen" Emerges as Alzheimer's and Rare Disease Pipelines Take Center Stage
Via MarketMinute
Topics Intellectual Property
News headline image
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire
News headline image
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
From Denali Therapeutics Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Denali Therapeutics Inc. - Common Stock publicly traded?
Yes, Denali Therapeutics Inc. - Common Stock is publicly traded.
What exchange does Denali Therapeutics Inc. - Common Stock trade on?
Denali Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Denali Therapeutics Inc. - Common Stock?
The ticker symbol for Denali Therapeutics Inc. - Common Stock is DNLI on the Nasdaq Stock Market
What is the current price of Denali Therapeutics Inc. - Common Stock?
The current price of Denali Therapeutics Inc. - Common Stock is 24.00
When was Denali Therapeutics Inc. - Common Stock last traded?
The last trade of Denali Therapeutics Inc. - Common Stock was at 08/28/26 04:00 PM ET
What is the market capitalization of Denali Therapeutics Inc. - Common Stock?
The market capitalization of Denali Therapeutics Inc. - Common Stock is 2.92B
How many shares of Denali Therapeutics Inc. - Common Stock are outstanding?
Denali Therapeutics Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story